24 02 02 patent wound gel

CS MEDICA A/S Achieves New Milestone with Patent on their Wound Care Treatment.

CS MEDICA received its third-issued patent on its “Wound Gel,” offering an advanced healing process for wounds such as minor abrasionscuts, burns, and sunburns.

CS MEDICA A/S (“CS MEDICA” or “The Company”), an innovator in the healthcare industry, is proud to announce the recent patent approval for its Wound Gel, marked by the Danish Patent and Trademark Office under patent number DK 181458.

This achievement is the third patent granted to CS MEDICA in the past year, reinforcing the company’s commitment to innovation in healthcare. Moreover, the company has advanced its research and development efforts with several more patent-pending treatments currently under review.

CS MEDICA specializes in developing accessible, effective, and clinically tested healthcare products with fewer side effects, targeting pain management and skin care categories. The CANNASEN® Wound Gel represents an essential advancement in the company’s product portfolio, specifically designed to facilitate an optimal healing process of wounds such as minor abrasions, cuts, burns, and sunburns.


02 02 24 Patent Woundgel

Lone Henriksen, CEO and founder of CS MEDICA states, “The approval of this patent, our third within a year, is a commitment to our focused approach towards healthcare innovation. Importantly, we are progressing with several more treatments pending patent approval, validating our purpose to deliver innovative healthcare solutions to 2- and 4-legged patients globally.

Lone continues, “Being a first-mover combining science with the therapeutical benefits of cannabinoids, under strict compliance and regulatory rules holds challenges, but this is a recognition for us to continue focusing on providing efficient, over-the-counter alternative treatments to the market.



About the Wound Gel

The Wound Gel is a CE-marked substance-based medical device proven for its safety and effectiveness. Features include:

  • A unique, patented formula that promotes an advanced healing process.
  • Applicability across a broad user base (launched as Wound Gel in the CANNASEN® brand and as White Label solutions. Also available as Make-to-Order for aminal treatments).
  • Documentation affirming its efficacy as a medical device.

For more information on the Wound Gel and other products by CS MEDICA, please visit cannasen.com or cs-medica.com





This disclosure contains information that CS MEDICA A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-02-2024 14:38 CET.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA is a Danish-based MedTech company operating within research, development, manufacturing, commercializing, and operating within the pharmaceutical industry. The company combines science and nature with the purpose of creating over-the-counter treatments to fight autoimmune and stress-related diseases, built upon our knowledge of the endocannabinoid system, patients’ needs, and our experience in the pharmaceutical industry. We do so by pioneering scientific breakthroughs, expanding access to our treatments, understanding patients globally, and working to prevent the pain caused by the diseases we treat.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.